Dr. Shin has developed novel reagents designed to target micrometastatic disease. His long term research goal has been to develop therapeutic anti-tumor antibody fusion proteins, which employ the targeting flexibility of antibodies to direct localization of biological active molecules to the tumor site, and to investigate potential mechanisms of anti-tumor efficacy. He will study mechanisms by which antibody-endostatin fusion proteins inhibit angiogenesis and/or vasculogenic mimicry (VM) which may contribute to the formation of capillary like vascular channel structures in tumors, and whether antibody-endostatin fusion proteins used will prove more effective in tumors.